The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence

Pancreatic cancer is one of the most lethal malignancies with a rise in mortality rates. FOLFIRINOX and nab-paclitaxel plus gemcitabine demonstrated a survival benefit compared to gemcitabine alone. Both protocols are now considered the standard of first-line treatment with no significant difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Prejac, Juraj, Tomek Hamzić, Dora, Librenjak, Nikša, Goršić, Irma, Kekez, Domina, Pleština, Stjepko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524920/
https://www.ncbi.nlm.nih.gov/pubmed/36181099
http://dx.doi.org/10.1097/MD.0000000000030566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524920/
https://www.ncbi.nlm.nih.gov/pubmed/36181099
http://dx.doi.org/10.1097/MD.0000000000030566

Ejemplares similares